Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.

Lignende værker

• FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.
  af: Mead, A, et al.
  Udgivet: (2007)
• The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.
  af: Gale, R, et al.
  Udgivet: (2008)
• A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
  af: Knapper, S, et al.
  Udgivet: (2017)
• FLT3, NPM1, DNMT3a and NRAS genes mutation in acute myeloid leukaemia in HUSM
  af: Mat Yunus, Noraini
  Udgivet: (2015)
• SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia
  af: Puissant, Alexandre, et al.
  Udgivet: (2017)